Latest & greatest articles for sepsis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sepsis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sepsis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sepsis

401. Effects of ibuprofen on the physiology and survival of hypothermic sepsis

Effects of ibuprofen on the physiology and survival of hypothermic sepsis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club1999

402. Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis

Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis Jenson H B, Pollock B H Authors' objectives To determine the effectiveness of intravenous immune globulin (IVIG) in the prevention and treatment of neonatal (...) sepsis. Searching MEDLINE (no dates given) was searched for English language papers plus identification of studies by "personal knowledge". Study selection Study designs of evaluations included in the review Peer-reviewed, prospective randomised trials including a concurrent control group receiving either placebo or no IVIG treatment were eligible for inclusion. IVIG administration had to be given shortly after birth for prophylaxis, or on clinical diagnosis of sepsis for treatment. Specific

DARE.1997

403. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group.

Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. 9020273 1997 02 20 1997 02 20 2016 10 17 0098-7484 277 6 1997 Feb 12 JAMA JAMA Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled (...) trial. CP-0127 SIRS and Sepsis Study Group. 482-7 To test the effect of a novel bradykinin antagonist, deltibant (CP-0127), on survival, organ dysfunction, and other outcomes in patients with the systemic inflammatory response syndrome (SIRS) and presumed sepsis. Multicenter, randomized, placebo-controlled, double-blind, parallel, dose-ranging trial. Follow-up for 28 days or until death. A total of 47 US referral hospitals. A total of 504 patients with SIRS and documented evidence of infection plus

JAMA1997

404. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.

The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. 9070471 1997 03 27 1997 03 27 2013 11 21 0028-4793 336 13 1997 Mar 27 The New England journal of medicine N. Engl. J. Med. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. 912-8 In patients with sepsis the production of arachidonic acid metabolites by cyclooxygenase increases, but the pathophysiologic role (...) of these prostaglandins is unclear. In animal models, inhibition of cyclooxygenase by treatment with ibuprofen before the onset of sepsis reduces physiologic abnormalities and improves survival. In pilot studies of patients with sepsis, treatment with ibuprofen led to improvements in gas exchange and airway mechanics. From October 1989 to March 1995, we conducted a randomized, double-blind, placebo-controlled trial of intravenous ibuprofen (10 mg per kilogram of body weight [maximal dose, 800 mg], given every six

NEJM1997

405. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.

p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. 9153367 1997 05 29 1997 05 29 2016 10 17 0098-7484 277 19 1997 May 21 JAMA JAMA p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. 1531-8 To evaluate the safety and efficacy of p55 (...) tumor necrosis factor receptor fusion protein, a recombinant chimeric protein of human p55 (type I) tumor necrosis factor receptor (CD120a) extracellular domain and IgG1 sequences (referred to as p55-IgG), in the treatment of patients with severe sepsis or septic shock. Randomized, prospective, multicenter, double-blind, placebo-controlled clinical trial. Forty-four community and university-affiliated hospitals in the United States and Europe. There were 498 patients enrolled in this clinical trial

JAMA1997

406. Percutaneous central venous catheter-related sepsis in the neonate: an analysis of the literature from 1990 to 1994

Percutaneous central venous catheter-related sepsis in the neonate: an analysis of the literature from 1990 to 1994 Percutaneous central venous catheter-related sepsis in the neonate: an analysis of the literature from 1990 to 1994 Percutaneous central venous catheter-related sepsis in the neonate: an analysis of the literature from 1990 to 1994 Trotter C W Authors' objectives To evaluate methods of reducing catheter-related sepsis (CRS) in high-risk neonates. Searching MEDLINE, CINAHL (...) on the methods of this review. Literature searches were performed from 1990 onwards as the author states that she had previously reviewed literature published prior to 1990; however, no reference for this is provided. Implications of the review for practice and research There is a need for randomised controlled trials of methods to reduce CRS. Bibliographic details Trotter C W. Percutaneous central venous catheter-related sepsis in the neonate: an analysis of the literature from 1990 to 1994. Neonatal

DARE.1996

407. Randomized, placebo-controlled, double blinded trial of dexamethasone in African children with sepsis

Randomized, placebo-controlled, double blinded trial of dexamethasone in African children with sepsis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club1996

408. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. 8637514 1996 07 05 1996 07 05 2006 11 15 0028-4793 334 26 1996 Jun 27 The New England journal of medicine N. Engl. J. Med. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. 1697-702 A recombinant, soluble fusion protein that is a dimer of an extracellular portion of the human tumor

NEJM1996

409. Effect of subcutaneous tunneling on internal jugular catheter-related sepsis in critically ill patients: a prospective randomized multicenter study.

Effect of subcutaneous tunneling on internal jugular catheter-related sepsis in critically ill patients: a prospective randomized multicenter study. 8892717 1996 11 26 1996 11 26 2016 10 17 0098-7484 276 17 1996 Nov 06 JAMA JAMA Effect of subcutaneous tunneling on internal jugular catheter-related sepsis in critically ill patients: a prospective randomized multicenter study. 1416-20 To evaluate the effect of catheter tunneling on internal jugular catheter-related sepsis in critically ill (...) catheters. Times to occurrence of systemic catheter-related sepsis, catheter-related septicemia, or a quantitative catheter-tip culture with a cutoff of 103 colony-forming units per milliliter. A total of 241 patients were randomized. Ten patients in whom jugular puncture was not achieved were subsequently excluded. The proportion of patients receiving mechanical ventilation (87%) and mean+/-SD age (65+/-4 years), Simplified Acute Physiologic Score (13.3+/-4.9), Organ System Failure score (1.5+/-1.0

JAMA1996

410. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group.

Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. 8618579 1996 06 13 1996 06 13 2015 11 19 0028-4793 334 22 1996 May 30 The New England journal of medicine N. Engl. J. Med. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. 1417-21 Patients with acute respiratory distress syndrome (ARDS (...) ) have a deficiency of surfactant. Surfactant replacement improves physiologic function in such patients, and preliminary data suggest that it may improve survival. We conducted a prospective, multicenter, double-blind, randomized, placebo-controlled trial involving 725 patients with sepsis-induced ARDS. Patients were stratified according to the risk of death at base line (indicated by their score on the Acute Physiological and Chronic Health Evaluation [APACHE III] index) and randomly assigned

NEJM1996

411. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. 7884952 1995 04 12 1995 04 12 2016 10 17 0098-7484 273 12 1995 Mar 22-29 JAMA JAMA Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb (...) Sepsis Study Group. 934-41 To evaluate the efficacy and safety of anti-tumor necrosis factor alpha monoclonal antibody (TNF-alpha MAb) in the treatment of patients with sepsis syndrome. Randomized, prospective, multicenter, double-blind, placebo-controlled clinical trial. A total of 31 hospitals in the United States and Canada. There were 994 patients with sepsis syndrome enrolled in this clinical trial, and 971 patients were infused with the study drug. Patients were prospectively stratified

JAMA1995

412. Early-onset neonatal group B streptococcal sepsis: economics of various prevention strategies

Early-onset neonatal group B streptococcal sepsis: economics of various prevention strategies Early-onset neonatal group B streptococcal sepsis: economics of various prevention strategies Early-onset neonatal group B streptococcal sepsis: economics of various prevention strategies Garland S M, Kelly N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Prevention strategies for early-onset neonatal group B streptococcal sepsis. Type of intervention Screening and primary prevention. Economic study type Cost-effectiveness analysis. Study population Pregnant women with and without obstetric risk factors. Setting The setting was hospital obstetric centres. Australian data were used where possible. Dates to which data relate

NHS Economic Evaluation Database.1995

413. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature

Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature Cronin L, Cook D J, Carlet J, Heyland D K, King D, Lansang M A, Fisher C J Authors' objectives To determine the effect of corticosteroid therapy on morbidity and mortality in patients with sepsis. Searching MEDLINE (...) and EMBASE were searched from 1966 to 1993 using the following MeSH terms: 'sepsis' and 'steroids' or 'corticosteroids', and 'septic shock and 'steroids' or 'corticosteroids'. The Science Citation Index was searched using the terms 'sepsis' and (explode) 'corticosteroid', and 'septic shock' and (explode) 'corticosteroid'. Index Medicus was handsearched from 1951 onwardusing the terms 'corticosteroids', 'steroids', 'sepsis' and 'septic shock'. Personal files, reference lists of relevant primary and review

DARE.1995

414. Steroid controversy in sepsis and septic shock: a meta-analysis

Steroid controversy in sepsis and septic shock: a meta-analysis Steroid controversy in sepsis and septic shock: a meta-analysis Steroid controversy in sepsis and septic shock: a meta-analysis Lefering R, Neugebauer E A Authors' objectives To conduct a meta-analysis to asses the clinical evidence for the use of corticosteroids on patients with septic shock, and to evaluate treatment effects in specific subgroups of patients. Searching MEDLINE was searched from 1966 to 1992. The authors' own (...) literature file, and references in trial reports and review articles, were also examined. Experts in the field of sepsis research were contacted for additional material. Study selection Study designs of evaluations included in the review Prospective randomised controlled trials (RCTs), which evaluated the effectiveness of corticosteroids in the management of septic shock, were included if they fulfilled the following criteria: a primary intention to assess the effectiveness of corticosteroids, a control

DARE.1995

415. Accuracy of leukocyte indices and C-reactive protein for diagnosis of neonatal sepsis: a critical review

Accuracy of leukocyte indices and C-reactive protein for diagnosis of neonatal sepsis: a critical review Accuracy of leukocyte indices and C-reactive protein for diagnosis of neonatal sepsis: a critical review Accuracy of leukocyte indices and C-reactive protein for diagnosis of neonatal sepsis: a critical review Da Silva O, Ohlsson A, Kenyon C Authors' objectives To evaluate the accuracy of C-reactive protein (CRP) and leukocyte indices in the diagnosis of infants suspected of having (...) septicaemia in a neonatal intensive care setting. Searching EMBASE and MEDLINE were searched from 1988 and 1966, respectively, to May 1994 using the following search terms: 'infant', 'new-born', 'C-reactive protein', 'leukocyte count', and 'sepsis' or 'septicaemia' or 'infection'. The bibliographies of primary and review articles were also searched, as were the authors' personal files. No language restrictions were applied. Study selection Study designs of evaluations included in the review No inclusion

DARE.1995

416. The influence of clinical study design on cost-effectiveness projections for the treatment of Gram-negative sepsis with human anti-endotoxin antibody

The influence of clinical study design on cost-effectiveness projections for the treatment of Gram-negative sepsis with human anti-endotoxin antibody The influence of clinical study design on cost-effectiveness projections for the treatment of Gram-negative sepsis with human anti-endotoxin antibody The influence of clinical study design on cost-effectiveness projections for the treatment of Gram-negative sepsis with human anti-endotoxin antibody Linden P K, Angus D C, Chelluri L, Branch R (...) A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using human anti-endotoxin antibody (HA-1A) in patients with sepsis and suspicion of gram-negative bacteremia (GNB). Type of intervention Treatment. Economic study type Cost

NHS Economic Evaluation Database.1995

417. Corticosteroids treatment for sepsis: a critical appraisal and meta-analysis of the literature

Corticosteroids treatment for sepsis: a critical appraisal and meta-analysis of the literature PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club1995

418. Steroid controversy in sepsis and septic shock: A meta-analysis.

Steroid controversy in sepsis and septic shock: A meta-analysis. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club1995

419. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. 8196140 1994 06 30 1994 06 30 2016 10 17 0098-7484 271 23 1994 Jun 15 JAMA JAMA Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis (...) Syndrome Study Group. 1836-43 To further define the safety and efficacy of recombinant human interleukin 1 receptor antagonist (rhIL-1ra) in the treatment of sepsis syndrome. Randomized, double-blind, placebo-controlled, multicenter, multinational clinical trial. A total of 893 patients with sepsis syndrome received an intravenous loading dose of rhIL-1ra, 100 mg, or placebo followed by a continuous 72-hour intravenous infusion of rhIL-1ra (1.0 or 2.0 mg/kg per hour) or placebo. Twenty-eight-day all

JAMA1994

420. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis.

The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. 7933396 1994 11 16 1994 11 16 2016 10 17 0098-7484 272 17 1994 Nov 02 JAMA JAMA The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. 1354-7 To compare the effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in patients with hyperdynamic sepsis. A randomized short-term (...) whereas the pHi decreased significantly in those patients receiving dopamine (P < .001, for corrected 3-hour value). This study suggests that dopamine may cause an uncompensated increase in splanchnic oxygen requirements in septic patients. Norepinephrine, however, may have a more favorable hemodynamic profile and improve splanchnic tissue oxygen utilization in sepsis. Marik P E PE Division of Critical Care Medicine, Detroit (Mich) Receiving Hospital. Mohedin M M eng Clinical Trial Journal Article

JAMA1994